Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 39,500 shares, a growth of 9.7% from the June 30th total of 36,000 shares. Based on an average daily volume of 9,100 shares, the short-interest ratio is currently 4.3 days. Approximately 1.7% of the company’s stock are short sold.
Shares of NASDAQ:ETTX traded up $0.05 during trading on Wednesday, reaching $7.25. 8,000 shares of the company’s stock traded hands, compared to its average volume of 10,942. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.79 and a quick ratio of 8.79. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70. The company’s 50 day moving average is $6.46. The stock has a market cap of $97.83 million and a PE ratio of -0.59.
Entasis Therapeutics (NASDAQ:ETTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.44). On average, research analysts anticipate that Entasis Therapeutics will post -3.39 EPS for the current year.
An institutional investor recently bought a new position in Entasis Therapeutics stock. BlackRock Inc. acquired a new stake in shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned about 0.11% of Entasis Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 65.04% of the company’s stock.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Story: Coverage Ratio
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.